1,3,7-Trimethylxanthine as a Treatment of COVID-19: Results of a Controlled Study (TMX COVID)

Poitiers University Hospital

Status: Unknown

Conditions: Coronavirus Disease 2019

Treatments: Other: Data collection

Study type: Observational

Funder types: Other

Identifiers

NCT04395742

TMX COVID

Details and patient eligibility

About

This is observational study to assess the prognosis of patients hospitalized with COVID-19 confirmed by RT-PCR and exposed to trimethylxanthine (TMX).

Trimethylxanthine is the active molecule present in coffee. Due to the lack of etiologic treatments and considering interest about old treatments as an avenue for research, we conducted a comparative study aiming to evaluate the effect of 1,3,7-trimethylxanthine on COVID-19 infected patients. This is actually a study about methodology.

The objective of this study is therefore not to demonstrate the effect of the substance on the disease but the importance of a rigorous methodology in scientific research. This project is called "Method and Teaching of Scientific Studies".

Enrollment: 93 estimated patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18,
• No Trimethylxanthine contraindications (defined as allergy, previous reported secondary effects),
• Infectious Disease Unit admission.

Exclusion criteria

• Secondary effects about Trimethylxanthine,
• Refuse to participate

Trial design

93 participants in 2 patient groups

Coffee:1,3,7-trimethylxanthine

Treatment:

Other: Data collection

Tea and hot chocolate with milk

Treatment:

Other: Data collection